RE:RE:RE:It’s allllllll talkSo I buy into this ramble as well. This is RDW's legacy and it's something he spent a lifetime building. The science is there and I've invested in other biotech stock where they had massive funding but no product. This is the polar opposite where there is little to no funding but an incredibly promising product.
As to why RDW isn't able to raise more money or speculation on not wanting to relinquish control, that's very complicated and we'd end up down a rabbit hole. Instead, I'll try to keep my assumptions as simple as possible:
- Great Science with endless possibilities (recent news)
- A catalyst coming hopefully by 2024 (BTD)
- A legacy company for it's founder.
- The ability to lower their expenses drastically by not taking a paycheck until aforementioned catalyst.
Now the other side:
- Missteps from the management side again and again (Not reading between the lines on FDA reqs, as evidenced by the investor general meeting)
- Continuous delays in BTD timelines (Again, due to mismangement)
- Running dangerously low on cash (Can extend runway by reducing salary)
Based on those overly simple assumptions, it helps me sleep better. Good luck to everyone and have a wonderful long weekend.